161 related articles for article (PubMed ID: 27119977)
1. Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.
Matsukawa T; Hashimoto D; Sugita J; Nakazawa S; Matsushita T; Kashiwazaki H; Goto H; Onozawa M; Kahata K; Fujimoto K; Endo T; Kondo T; Hashino S; Yamazaki Y; Teshima T
Int J Hematol; 2016 Jul; 104(1):117-24. PubMed ID: 27119977
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
3. Minimum-Dose, Short-Term Methotrexate With Tacrolimus for Graft-vs-Host Disease Prophylaxis Following Unrelated Cord Blood Transplantation in Adults: A Retrospective Analysis at a Single Institution.
Iino M; Sato T; Sakamoto Y
Transplant Proc; 2021; 53(1):396-404. PubMed ID: 33308840
[TBL] [Abstract][Full Text] [Related]
4. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.
Freyer CW; Gier S; Moyer ME; Berryman N; Carulli A; Ganetsky A; Timlin C; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy S; Perl AE; Smith J; Luger SM; Stadtmauer EA; Porter DL
Transplant Cell Ther; 2021 May; 27(5):431.e1-431.e8. PubMed ID: 33965188
[TBL] [Abstract][Full Text] [Related]
5. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Yoshida S; Ohno Y; Nagafuji K; Yoshimoto G; Sugio T; Kamimura T; Ohta T; Takase K; Henzan H; Muta T; Iwasaki H; Ogawa R; Eto T; Akashi K; Miyamoto T
Ann Hematol; 2019 Nov; 98(11):2579-2591. PubMed ID: 31628517
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
[TBL] [Abstract][Full Text] [Related]
7. GVHD prophylaxis by tacrolimus and mini-MTX in single-unit CBT: a single institute experience.
Fuji S; Tada Y; Nakata R; Nakata K; Koike M; Kida S; Tsutsumi K; Masaie H; Yoshida H; Ishikawa J
Int J Hematol; 2020 Feb; 111(2):278-283. PubMed ID: 31659626
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
Iguchi A; Terashita Y; Sugiyama M; Ohshima J; Sato TZ; Cho Y; Kobayashi R; Ariga T
Pediatr Transplant; 2016 Feb; 20(1):114-9. PubMed ID: 26526424
[TBL] [Abstract][Full Text] [Related]
9. Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Shiratori S; Ohigashi H; Takahashi S; Ara T; Goto H; Nakagawa M; Sugita J; Onozawa M; Kahata K; Endo T; Hashimoto D; Teshima T;
Ann Hematol; 2020 Mar; 99(3):591-598. PubMed ID: 32006152
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
12. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
13. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation.
Adachi M; Yokota D; Hirata H; Koyauchi K; Dohtan S; Oka S; Sakamoto N; Takaba M; Takemura T; Nagata Y; Naito K; Ono T
Int J Hematol; 2021 Aug; 114(2):252-262. PubMed ID: 34086252
[TBL] [Abstract][Full Text] [Related]
15. Umbilical cord blood transplantation for adults using tacrolimus with two-day very-short-term methotrexate for graft-versus-host disease prophylaxis.
Saito B; Hattori N; Yamamoto K; Arai N; Kawaguchi Y; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Nakamaki T
Leuk Res; 2016 Aug; 47():161-5. PubMed ID: 27376545
[TBL] [Abstract][Full Text] [Related]
16. Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity.
Kim SY; Kim AR; Yoon SY; Cho YH; Lee MH
Ann Hematol; 2016 Feb; 95(3):483-91. PubMed ID: 26658911
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
18. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
